Nanovaccine achieved tumour inhibition rate of 89.3 per cent when tested on mice with aggressive form of the disease, study finds.

The efficacy of immunotherapy against triple-negative breast cancer (TNBC) heavily relies on intratumoral infiltration of ...

An injectable hydrogel platform shows promise in local immunotherapy for triple-negative breast cancer, enhancing treatment ...

The efficacy of immunotherapy against triple-negative breast cancer (TNBC) heavily relies on intratumoral infiltration of cytotoxic T lymphocytes ...

The quadrivalent HPV vaccine, developed by multinational pharmaceutical company Merck, was approved on Jan 8 for males on the Chinese mainland. The vaccine targets HPV types 6, 11, 16 and 18. The ...

SHANGHAI & CAMBRIDGE ... 4 Phase 3 IMpower133 (atezolizumab) and CASPIAN study (durvalumab). 5 National Cancer Institute. www.cancer.gov. Accessed October 15, 2024. This press release contains ...

Hutchmed expects to record a gain of $477m from the deal and plans to invest the proceeds to develop its internal pipeline. See why I rate HCM stock a Hold.

Andrew Teschendorff, Professor at the Chinese Academy of Sciences, is developing computational systems-biological tools to ...

These consortia vary in their scope, funding, and structure from government-funded models such as the National Cancer Institute Experimental Therapeutics ... Qilu Puget Sound Biotherapeutics (Inst), ...